Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Bone lesions in recurrent glucagonoma: A case report and review of literature.

Ghetie C, Cornfeld D, Ramfidis VS, Syrigos KN, Saif MW.

World J Gastrointest Oncol. 2012 Jun 15;4(6):152-5. doi: 10.4251/wjgo.v4.i6.152.

2.

Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report.

Watt DG, Pandanaboyana S, Herrington CS, Tait IS.

JOP. 2013 Sep 10;14(5):510-4. doi: 10.6092/1590-8577/1622.

3.

Malignant glucagonoma. New options of treatment.

Appetecchia M, Ferretti E, Carducci M, Izzo F, Carpanese L, Marandino F, Terzoli E.

J Exp Clin Cancer Res. 2006 Mar;25(1):135-9.

PMID:
16761630
4.

[A case of pancreatic glucagonoma].

Simonenko VB, Dulin PA, Beliaev LB, Makanin MA, Dem'ianenko AV, Zykova AA, Zhuravleva SI, Kolesnikova VN.

Klin Med (Mosk). 2007;85(8):67-70. Russian.

PMID:
17926496
5.

Rare presentation of endocrine pancreatic tumor: a case of diffuse glucagonoma without metastasis and necrolytic migratory erythema.

Chen HW, Chen HW, Su DH, Shun CT, Liu KL.

J Formos Med Assoc. 2005 May;104(5):363-6.

PMID:
15959605
6.

Treatment of metastatic glucagonoma to the liver: case report and literature review.

Casadei R, Tomassetti P, Rossi C, la Donna M, Migliori M, Marrano D.

Ital J Gastroenterol Hepatol. 1999 May;31(4):308-12. Review.

PMID:
10425577
7.

An immunohistochemical study of glucagonoma conducted on the metastatic lymph nodes from a patient with recurrent metastatic glucagonoma: report of a case.

Kawakita N, Nagahata Y, Yoshizumi K, Wada T, Yamamoto M, Saitoh Y, Urakawa T.

Surg Today. 1994;24(10):918-22.

PMID:
7894192
8.

Diagnostic challenge of glucagonoma: case report and literature review.

Cruz-Bautista I, Lerman I, Perez-Enriquez B, Padilla LS, Torres CL, Lopez A, Cabrera T, Mehta RP, Gómez-Pérez FJ, Rull JA, Orozco-Topete R.

Endocr Pract. 2006 Jul-Aug;12(4):422-6.

PMID:
16901799
9.

[Glucagon-secreting malignant neuroendocrine tumor of the pancreas].

Wickenhauser C, Aichelmann E, Neuhaus H, Hölscher AH, Dienes HP.

Med Klin (Munich). 2000 Aug 15;95(8):466-9. German.

PMID:
10985071
10.

Glucagonoma syndrome: a case report.

Shyr YM, Su CH, Lee CH, Wu CW, Lui WY.

Zhonghua Yi Xue Za Zhi (Taipei). 1999 Sep;62(9):639-43. Review.

PMID:
10502856
11.

[Glucagonoma without glucagonoma syndrome].

Colović R, Matić S, Micev M, Grubor N, Latincić S.

Srp Arh Celok Lek. 2010 Mar-Apr;138(3-4):244-7. Serbian.

12.

Spinal metastasis as the initial manifestation of a nonsecretory glucagonoma.

Aggarwal A, Brainard J, Brotman DJ.

South Med J. 2003 Feb;96(2):190-3.

PMID:
12630646
13.

Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide.

Oberkirchner U, Linder KE, Zadrozny L, Olivry T.

Vet Dermatol. 2010 Oct;21(5):510-6. doi: 10.1111/j.1365-3164.2009.00876.x. Epub 2010 May 24.

PMID:
20500495
14.

[Diagnosis of glucagonoma. Value of scanning, echography and arteriography. Apropos of 2 cases and a review of the literature].

Hercot O, Legmann P, Humbert M, Sibert A, Somveille E, Picard C, Mignon M, Benacerraf R.

J Radiol. 1989;70(4):309-16. Review. French.

PMID:
2552085
15.

[Clinical response of an atypical glucagonoma treated with a long-acting somatostatin analog].

Bouin M, Aoust LD.

Gastroenterol Clin Biol. 2002 Oct;26(10):926-9. French.

16.

Paediatric necrolytic migratory erythema as a presenting sign of glucagonoma syndrome.

Luber AJ, Ackerman LS, Culpepper KS, Buschmann CM, Koep LJ.

Br J Dermatol. 2016 May;174(5):1092-1095. doi: 10.1111/bjd.14298. Epub 2016 Jan 20.

PMID:
26585841
17.

Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry.

Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, Thiéfin G, Cadiot G; Groupe des Tumeurs Endocrines.

Gastroenterol Clin Biol. 2004 Nov;28(11):1075-81.

18.

Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.

Makis W, McCann K, Riauka TA, McEwan AJ.

Clin Nucl Med. 2015 Nov;40(11):877-9. doi: 10.1097/RLU.0000000000000891.

PMID:
26204206
19.

Multimodality treatment of unresectable hepatic metastases from pancreatic glucagonoma.

Poggi G, Villani L, Bernardo G.

Rare Tumors. 2009 Jul 22;1(1):e6. doi: 10.4081/rt.2009.e6.

20.

Glucagonoma syndrome associated with necrolytic migratory erythema.

Cardoso Filho Fde A, Feitosa RG, Fechine CO, Matos CM, Cardoso AL, Cardoso DL.

Rev Assoc Med Bras (1992). 2015 May-Jun;61(3):203-6. doi: 10.1590/1806-9282.61.03.203.

Supplemental Content

Support Center